Regulatory affairs in an ideal world
This article was originally published in SRA
Parvinder Punia takes a look at the challenges today's pharmaceutical companies face when attempting a single global development and evaluates how things might be different were a single global overseeing agency to exist. Her analysis explores how current region-specific needs are being utilized to protect individual territorial markets and how these regional differences affect the access of poverty-stricken countries to medicine.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.